

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.

Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,

Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884¹

**DECLARATION OF MATTHEW M. WILK IN SUPPORT OF
MOTION FOR ADMISSION *PRO HAC VICE***

¹ IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

I, Matthew M. Wilk, do hereby declare as follows:

1. I am a member in good standing of the New York State Bar, to which I was admitted on December 10, 2018, and the Massachusetts State Bar, to which I was admitted on June 24, 2019.

2. I am a senior associate at the law firm of Arnold & Porter Kaye Scholer LLP (“Arnold & Porter”). I began working at Arnold & Porter in February 2020. I have pharmaceutical patent litigation experience, including in United States District Courts and before the Patent Trial & Appeal Board. My patent litigation experience includes cases related to biologics and medical devices.

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. I have never had an application for admission to practice before any court or administrative body denied.

5. I have had no sanctions or contempt citations imposed against me by any court or administrative body.

6. I have read and will comply with the Office Patent Trial Practice Guide and the Board’s Rules of Practice for Trials set forth in 37 C.F.R. § 42.

7. I agree to be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

8. I have applied to appear *pro hac vice* in the following proceedings before the USPTO: IPR2021-00880, IPR2021-00881, IPR2022-01225, IPR2022-01226, and IPR2023-00442. The USPTO granted my *pro hac vice* application in IPR2021-00880, IPR2021-00881, IPR2022-01225, IPR2022-01226, and IPR2023-00442.

9. Adam R. Brausa (Reg. 60,287) is an experience registered patent attorney with whom I have worked in this proceeding and will continue to do so.

10. I have significant familiarity with the subject matter at issue in this proceeding and have substantive knowledge of the patent at issue (U.S. Patent No. 11,253,572 (the “’572 Patent”)) by virtue of my preparation for this proceeding. A significant amount of my time since March 2020 has been spent working on issues related to the ’572 Patent, related patents, and Patent Owner’s commercial product, Eylea. Therefore, I have a substantial familiarity with the subject matter of this proceeding.

11. I hereby declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that all statements made of my own knowledge are true and that all statements made on information and belief

IPR2023-00884

are believed to be true. I understand that willful false statements are punishable by fine or imprisonment or both. See 18 U.S.C. § 1001.

Dated: March 13, 2024

/Matthew M. Wilk/
Mathew M. Wilk